You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 8, 2024

Investigational Drug Information for Losmapimod


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Losmapimod?

Losmapimod is an investigational drug.

There have been 15 clinical trials for Losmapimod. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2022.

The most common disease conditions in clinical trials are Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophies, and Lung Diseases. The leading clinical trial sponsors are GlaxoSmithKline, Fulcrum Therapeutics, and Royal Brompton & Harefield NHS Foundation Trust.

There are sixty-four US patents protecting this investigational drug and nine hundred and eighty-four international patents.

Recent Clinical Trials for Losmapimod
TitleSponsorPhase
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)Fulcrum TherapeuticsPhase 3
Relative Bioavailability and Food Effect Study of Losmapimod 15 mg TabletsFulcrum TherapeuticsPhase 1
Losmapimod Safety and Efficacy in COVID-19Fulcrum TherapeuticsPhase 3

See all Losmapimod clinical trials

Clinical Trial Summary for Losmapimod

Top disease conditions for Losmapimod
Top clinical trial sponsors for Losmapimod

See all Losmapimod clinical trials

US Patents for Losmapimod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Losmapimod ⤷  Sign Up Compounds .alpha..sub.v.beta..sub.6 integrin antagonists GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) ⤷  Sign Up
Losmapimod ⤷  Sign Up Inhalable pharmaceutical compositions iCeutica Pty Ltd. (Iluka, WA, AU) ⤷  Sign Up
Losmapimod ⤷  Sign Up 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors Chiesi Farmaceutici S.p.A. (Parma, IT) ⤷  Sign Up
Losmapimod ⤷  Sign Up Aminoester derivatives CHIESI FARMACEUTICI S.p.A. (Parma, IT) ⤷  Sign Up
Losmapimod ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Losmapimod ⤷  Sign Up Isoxazolidine derivatives CHIESI FARMACEUTICI S.p.A. (Parma, IT) ⤷  Sign Up
Losmapimod ⤷  Sign Up Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Losmapimod

Drugname Country Document Number Estimated Expiration Related US Patent
Losmapimod Argentina AR101995 2034-09-26 ⤷  Sign Up
Losmapimod Australia AU2015320859 2034-09-26 ⤷  Sign Up
Losmapimod Brazil BR112017006253 2034-09-26 ⤷  Sign Up
Losmapimod Canada CA2962326 2034-09-26 ⤷  Sign Up
Losmapimod China CN107074849 2034-09-26 ⤷  Sign Up
Losmapimod European Patent Office EP3197893 2034-09-26 ⤷  Sign Up
Losmapimod Spain ES2704525 2034-09-26 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.